Clusterin confers gmcitabine resistance in pancreatic cancer

详细信息    查看全文

• 作者：Qingfeng Chen (1)
  Zhengkun Wang (1)
  Kejun Zhang (1)
  Xiaoyi Liu (1)
  Weihong Cao (2)
  Lei Zhang (3)
  Shuhua Zhang (1)
  Bomin Yan (1)
  Yaoguang Wang (4) (5) (6)
  Chunping Xia (4) (5) (6)
  
• 刊名：World Journal of Surgical Oncology
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：9
• 期：1
• 全文大小：1908KB
• 参考文献：1. Arlt A, Gehrz A, M眉erk枚ster S, Vorndamm J, Kruse ML, F枚lsch UR, Sch盲fer H: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gmcitabine-induced cell death. / Oncogene 2003, 22:3243鈥?1. CrossRef
  2. Rosenberg ME, Silkensen J: Clusterin: Physiologic and pathophysiologic considerations. / Int J Biochem Cell Biol 1995, 27:633鈥?45. CrossRef
  3. Kyprianou N, English HF, Davison NE, Issac JT: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. / Cancer Res 1991, 51:162鈥?66.
  4. Wright PS, Cross-Doersen D, Th'ng JP, Guo XW, Crissman HA, Bradbury EM, Montgomery LR, / et al.: A ribonucleotide reductase inhibitor, MDL 101, 731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. / Exp Cell Res 1996, 222:54鈥?0. CrossRef
  5. Schwochau GB, Nath KA, Rosenberg ME: Clusterin protects against oxidative stress in vitro through aggressive and nonaggressive properties. / Kidney Int 1998, 53:1647鈥?653. CrossRef
  6. Savkovi膰 V, Gantzer H, Reiser U, / et al.: Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. / Biochem Biophys Res Commun 2007, 356:431鈥?. CrossRef
  7. Miyake H, Gleave M, Kamidono S, Hara I: Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. / Urology 2002, 59:150鈥?. CrossRef
  8. Lourda M, Trougakos IP, Gonos ES: Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein. / J Int J Cancer 2007, 12:611鈥?2. CrossRef
  9. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK: Overexpression of clusterin in human breast carcinoma. / Am J Pathol 2000, 157:393鈥?99. CrossRef
  10. Miyake H, Gleave ME, Arakawa S, Kamidomi S, Hara I: Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potentials. / J Urol 2002, 167:2003鈥?008.
  11. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES: Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. / Cancer Res 2004, 64:1834鈥?2. CrossRef
  12. Chung J, Kwak C, Jin RJ, Lee CH, Lee KH, Lee SE: Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. / Cancer Lett 2004, 203:155鈥?1. CrossRef
  13. Miyake H, Eto H, Hara I, So A, Li D, Gleave ME: Synergistic antitumor activity by combined treatment with gmcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. / J Urol 2004, 171:2477鈥?1. CrossRef
  14. Muramaki M, So A, Hayashi N, Sowery R, Miyake H, Fujisawa M, Gleave ME: Chemosensitization of gmcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. / BJU Int 2009, 103:384鈥?0. CrossRef
  15. Djeu JY, Wei S: Clusterin and chemoresistance. / Adv Cancer Res 2009, 105:77鈥?2. CrossRef
  16. Zhang K, Dong Chen, Jiao X, / et al.: Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. / Laboratory Investigation 2011, 1鈥?3.
  17. Fritz IB, Burdzy K, Setchell B, Blaschuk O: Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro. / Biol Reprod 1983, 28:1173鈥?188. CrossRef
  18. Trougakos IP, Gonos ES: Clusterin/apolipoprotein J in human aging and cancer. / Int J Biochem Cell Biol 2002, 34:1430鈥?448. CrossRef
  19. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, Reichrath J: Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. / Cell Death Differ 2006, 13:12鈥?9. CrossRef
  20. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY: Clusterin inhibits apoptosis by interacting with activated Bax. / Nat Cell Biol 2005, 7:909鈥?15. CrossRef
  21. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA: Synthesis and functional analyses of nuclear clusterin, a cell death protein. / J Biol Chem 2003, 278:11590鈥?1600. CrossRef
  22. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME: Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. / BJU Int 2008, 102:389鈥?7. CrossRef
  23. So A, Sinnemann S, Huntsman D, Fazli L, Gleave M: Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. / Mol Cancer Ther 2005, 4:1837鈥?9. CrossRef
  24. July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME: Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. / Mol Cancer Ther 2004, 3:223鈥?2.
  25. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME: Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. / Neoplasia 2001, 3:360鈥?. CrossRef
  26. Sheikh R, Walsh N, Clynes M, O'Connor R, McDermott R: Challenges of drug resistance in the management of pancreatic cancer. / Expert Rev Anticancer Ther 2010, 10:1647鈥?1. CrossRef
  27. Xie MJ, Motoo Y, Su SB, Mouri H, Ohtsubo K, Matsubara F, Sawabu N: Expression of clusterin in human pancreatic cancer. / Pancreas 2002, 25:234鈥?. CrossRef
  
• 作者单位：Qingfeng Chen (1)
  Zhengkun Wang (1)
  Kejun Zhang (1)
  Xiaoyi Liu (1)
  Weihong Cao (2)
  Lei Zhang (3)
  Shuhua Zhang (1)
  Bomin Yan (1)
  Yaoguang Wang (4) (5) (6)
  Chunping Xia (4) (5) (6)
  
  1. Surgery, the Affiliated Hospital of Medical College, QingDao University, QingDao, 266003, R.P. China
  2. Pathology, the Affiliated Hospital of Medical College, QingDao University, Shan Dong Province, 266003, P.R. China
  3. Molecular Biology, the Affiliated Hospital of Medical College, QingDao University, Shan Dong Province, 266003, P.R. China
  4. Hepatobiliary surgery, Tianjin Medical university Cancer Institute and Hospital, Tianjin, China, 300060
  5. Huanhuxi Road, Hexi District, Tianjin, China
  6. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
  

文摘

Objective To measure clusterin expression in pancreatic cancer tissues and cell lines and to evaluate whether clusterin confers resistance to gmcitabine in pancreatic cancer cells. Methods Immunohistochemistry for clusterin was performed on 50 primary pancreatic cancer tissues and 25 matched backgrounds, and clusterin expression in 5 pancreatic cancer cell lines was quantified by Western blot and PT-PCR. The correlation between clusterin expression level and gmcitabine IC50 in pancreatic cancer cell lines was evaluated. The effect of an antisense oligonucleotide (ASO) against clusterin(OGX-011) on gmcitabine resistance was evaluated by MTT assays. Xenograft model was used to demonstrate tumor growth. Results Pancreatic cancer tissues expressed significantly higher levels of clusterin than did normal pancreatic tissues (P < 0.01). Clusterin expression levels were correlated with gmcitabine resistance in pancreatic cancer cell lines, and OGX-011 significantly decreased BxPc-3 cells resistance to gmcitabine (P < 0.01). In vivo systemic administration of AS clusterin and gmcitabine significantly decreased the s.c. BxPC-3 tumor volume compared with mismatch control ODN plus gmcitabine. Conclusion Our finding that clusterin expression was significantly higher in pancreatic cancer than in normal pancreatic tissues suggests that clusterin may confer gmcitabine resistance in pancreatic cancer cells.